BRPI0112115B8 - compostos moduladores ppar-gamma de quinolinil e benzotiazolil - Google Patents
compostos moduladores ppar-gamma de quinolinil e benzotiazolilInfo
- Publication number
- BRPI0112115B8 BRPI0112115B8 BRPI0112115A BR0112115A BRPI0112115B8 BR PI0112115 B8 BRPI0112115 B8 BR PI0112115B8 BR PI0112115 A BRPI0112115 A BR PI0112115A BR 0112115 A BR0112115 A BR 0112115A BR PI0112115 B8 BRPI0112115 B8 BR PI0112115B8
- Authority
- BR
- Brazil
- Prior art keywords
- ppar
- benzothiazolyl
- quinolinyl
- compounds
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/36—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Photoreceptors In Electrophotography (AREA)
- Quinoline Compounds (AREA)
- Holo Graphy (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21481000P | 2000-06-28 | 2000-06-28 | |
| PCT/US2001/020756 WO2002000633A1 (en) | 2000-06-28 | 2001-06-27 | Quinolinyl and benzothiazolyl ppar-gamma modulators |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR0112115A BR0112115A (pt) | 2003-04-29 |
| BRPI0112115B1 BRPI0112115B1 (pt) | 2016-07-26 |
| BRPI0112115B8 true BRPI0112115B8 (pt) | 2021-05-25 |
Family
ID=22800496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0112115A BRPI0112115B8 (pt) | 2000-06-28 | 2001-06-27 | compostos moduladores ppar-gamma de quinolinil e benzotiazolil |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP1296967B1 (enExample) |
| JP (1) | JP4515026B2 (enExample) |
| KR (1) | KR100771286B1 (enExample) |
| CN (1) | CN1243741C (enExample) |
| AT (1) | ATE327984T1 (enExample) |
| AU (2) | AU2001271637B2 (enExample) |
| BR (1) | BRPI0112115B8 (enExample) |
| CA (1) | CA2412723C (enExample) |
| CY (1) | CY1105126T1 (enExample) |
| CZ (1) | CZ302982B6 (enExample) |
| DE (1) | DE60120163T2 (enExample) |
| DK (1) | DK1296967T3 (enExample) |
| EA (1) | EA005976B1 (enExample) |
| ES (1) | ES2265435T3 (enExample) |
| HK (1) | HK1052351B (enExample) |
| HU (1) | HUP0301482A3 (enExample) |
| IL (2) | IL153461A0 (enExample) |
| MX (1) | MXPA02012708A (enExample) |
| NO (1) | NO325448B1 (enExample) |
| NZ (1) | NZ523229A (enExample) |
| PL (1) | PL214670B1 (enExample) |
| PT (1) | PT1296967E (enExample) |
| SK (1) | SK288236B6 (enExample) |
| WO (1) | WO2002000633A1 (enExample) |
| ZA (1) | ZA200210283B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7041691B1 (en) | 1999-06-30 | 2006-05-09 | Amgen Inc. | Compounds for the modulation of PPARγ activity |
| US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
| US20030171399A1 (en) | 2000-06-28 | 2003-09-11 | Tularik Inc. | Quinolinyl and benzothiazolyl modulators |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| IL160845A0 (en) | 2001-09-14 | 2004-08-31 | Tularik Inc | Linked biaryl compounds |
| US6716842B2 (en) | 2002-04-05 | 2004-04-06 | Warner-Lambert Company, Llc | Antidiabetic agents |
| AU2003248549B2 (en) | 2002-05-24 | 2010-04-08 | Millennium Pharmaceuticals, Inc. | CCR9 inhibitors and methods of use thereof |
| US7741519B2 (en) | 2007-04-23 | 2010-06-22 | Chemocentryx, Inc. | Bis-aryl sulfonamides |
| AU2003298661B2 (en) | 2002-11-18 | 2007-05-10 | Chemocentryx, Inc. | Aryl sulfonamides |
| US7420055B2 (en) | 2002-11-18 | 2008-09-02 | Chemocentryx, Inc. | Aryl sulfonamides |
| US7227035B2 (en) | 2002-11-18 | 2007-06-05 | Chemocentryx | Bis-aryl sulfonamides |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| ES2530235T3 (es) | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| EP1613298A4 (en) * | 2003-04-11 | 2007-10-03 | Univ Tennessee Res Foundation | Lysophosphatidic Acid Analysis and Inhibition of Neointimal Formation |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| US7223761B2 (en) * | 2003-10-03 | 2007-05-29 | Amgen Inc. | Salts and polymorphs of a potent antidiabetic compound |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| DE602005020313D1 (de) | 2004-08-12 | 2010-05-12 | Amgen Inc | Bisaryl-sulfonamide |
| KR20110084339A (ko) | 2005-07-09 | 2011-07-21 | 아스트라제네카 아베 | 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체 |
| US7820721B2 (en) | 2006-01-25 | 2010-10-26 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP1976510A4 (en) | 2006-01-25 | 2010-06-09 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER |
| JP2009525982A (ja) | 2006-02-02 | 2009-07-16 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
| JP5291471B2 (ja) * | 2006-02-15 | 2013-09-18 | アボット・ラボラトリーズ | 新規なアセチル−ＣｏＡカルボキシラーゼ（ＡＣＣ）阻害薬およびこれらの糖尿病、肥満および代謝症候群における使用 |
| US8030324B2 (en) * | 2006-09-21 | 2011-10-04 | Piramal Life Sciences Ltd. | Pyridine derivatives for the treatment of metabolic disorders related to insulin resistance or hyperglycemia |
| WO2012162463A1 (en) * | 2011-05-25 | 2012-11-29 | Janssen Pharmaceutica Nv | Benzothiazolyl inhibitors of pro-matrix metalloproteinase activation |
| CN107683135A (zh) | 2015-03-09 | 2018-02-09 | 因特克林医疗有限公司 | 用于治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法 |
| AU2018249822A1 (en) | 2017-04-03 | 2019-10-31 | Coherus Biosciences Inc. | PPArgamma agonist for treatment of progressive supranuclear palsy |
| CN109651208B (zh) * | 2017-10-10 | 2022-01-04 | 中国科学院上海药物研究所 | N-芳基磺酰胺类化合物，其药物组合物及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3632329A1 (de) * | 1986-09-24 | 1988-03-31 | Bayer Ag | Substituierte phenylsulfonamide |
| AU759255B2 (en) * | 1998-01-29 | 2003-04-10 | Amgen, Inc. | PPAR-gamma modulators |
| WO2001000579A1 (en) * | 1999-06-30 | 2001-01-04 | Tularik Inc. | COMPOUNDS FOR THE MODULATION OF PPARη ACTIVITY |
-
2001
- 2001-06-27 HK HK03104574.3A patent/HK1052351B/en not_active IP Right Cessation
- 2001-06-27 PT PT01950669T patent/PT1296967E/pt unknown
- 2001-06-27 KR KR1020027017927A patent/KR100771286B1/ko not_active Expired - Lifetime
- 2001-06-27 EP EP01950669A patent/EP1296967B1/en not_active Expired - Lifetime
- 2001-06-27 IL IL15346101A patent/IL153461A0/xx active IP Right Grant
- 2001-06-27 MX MXPA02012708A patent/MXPA02012708A/es active IP Right Grant
- 2001-06-27 HU HU0301482A patent/HUP0301482A3/hu unknown
- 2001-06-27 PL PL359996A patent/PL214670B1/pl unknown
- 2001-06-27 AT AT01950669T patent/ATE327984T1/de active
- 2001-06-27 DK DK01950669T patent/DK1296967T3/da active
- 2001-06-27 CA CA2412723A patent/CA2412723C/en not_active Expired - Lifetime
- 2001-06-27 EA EA200300078A patent/EA005976B1/ru not_active IP Right Cessation
- 2001-06-27 CZ CZ20024197A patent/CZ302982B6/cs not_active IP Right Cessation
- 2001-06-27 NZ NZ523229A patent/NZ523229A/en not_active IP Right Cessation
- 2001-06-27 AU AU2001271637A patent/AU2001271637B2/en not_active Expired
- 2001-06-27 ES ES01950669T patent/ES2265435T3/es not_active Expired - Lifetime
- 2001-06-27 DE DE60120163T patent/DE60120163T2/de not_active Expired - Lifetime
- 2001-06-27 AU AU7163701A patent/AU7163701A/xx active Pending
- 2001-06-27 CN CNB018120172A patent/CN1243741C/zh not_active Expired - Lifetime
- 2001-06-27 JP JP2002505381A patent/JP4515026B2/ja not_active Expired - Lifetime
- 2001-06-27 SK SK1835-2002A patent/SK288236B6/sk not_active IP Right Cessation
- 2001-06-27 BR BRPI0112115A patent/BRPI0112115B8/pt not_active IP Right Cessation
- 2001-06-27 WO PCT/US2001/020756 patent/WO2002000633A1/en not_active Ceased
-
2002
- 2002-12-16 IL IL153461A patent/IL153461A/en unknown
- 2002-12-19 ZA ZA2002/10283A patent/ZA200210283B/en unknown
- 2002-12-20 NO NO20026156A patent/NO325448B1/no not_active IP Right Cessation
-
2006
- 2006-08-07 CY CY20061101099T patent/CY1105126T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0112115A (pt) | Compostos moduladores ppar-gamma de quinolinil e benzotiazolil | |
| ATE200760T1 (de) | Formular das unerlaubtes lesen erkennen lässt, zur sicheren übermittlung von informationen | |
| BR9714242A (pt) | Hidrosipropilcelulose metilada e produtos sensìveis `a temperatura fabricados a partir da mesma | |
| BR0011446A (pt) | Método de inibição da agregação de proteìna amilóide e formação de imagem de depósitos de amilóide usando derivados de isoindolina | |
| HUP9901132A2 (hu) | 2-Alkilpirrolidinek | |
| BR0315450A (pt) | Circuito eletrônico à prova de violação para implantação de um dispositivo, dispositivo implementado com um circuito eletrônico à proca de violação, e, métodos de gerenciamento de dados de segurança para um dispositivo, para manter segurança de dados em relação a comunicação de rede entre um dispositivo de rede e um parceiro de comunicação externa, e para marcar conteúdo digital produzido por um dispositivo de produção de conteúdo. | |
| EP0852770A4 (en) | Safe and low cost computer peripherals with force feedback for consumer applications | |
| BR0112033A (pt) | Método para tratamento de substratos minerais | |
| EP0840608A4 (en) | Treatment and prevention of neoplasms with salts of aminoimidazole carboxamide and 5-amino or substituted amino 1,2,3-triazoles | |
| NO20054989D0 (no) | 1,2,4-substituerte 1,2,3,4-tetrahydro og 1,2,dihydro-quinolin og 1,2,3,4-tetrahydro-quinoksalinderivater som CETP inhibitorer for behandlingen av aterosklerose og fedme | |
| ATE472992T1 (de) | Stabilisierung von körperpflegemittel und haushaltsmitteln | |
| PL366534A1 (en) | Network zones | |
| FI861995A0 (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2-(4-benzoyl-1-piperidinyl)-1 -fenylalkanolderivat. | |
| TR200201613T2 (tr) | Antitümör tesirli 2-(1H-indol-3-il)-2-okso asetamidler | |
| ATE207057T1 (de) | Aminostilbazolderivate und medikament | |
| ES2121440T3 (es) | Instalacion de plasma. | |
| NO991686L (no) | Anvendelse av sarkosinater som asfaltendispergatorer | |
| BR0212770A (pt) | Sais mandelato de derivados de tetrahidrofurano tetracìclico substituìdo | |
| NO994059L (no) | Vandig dispersjon for behandling av sugende materialer for aa beskytte mot tilsmussing | |
| FI972850A0 (fi) | Optisesti vaalennettujen muovien käyttö paperin päällystyslietteiden vaalentamiseksi optisesti ja tällä tavoin optisesti vaalennettuja paperin päällystyslietteitä | |
| BR0012072A (pt) | Processo para o tratamento ou prevenção de vasoespasmo de enxerto coronário | |
| BR0009856A (pt) | Sìntese de 3-amino-3-aril propanoatos | |
| BR9912000A (pt) | Uso de derivados de tetraidropiridina (ou 4-hipropiperidina)- butilazóis na preparação de medicamento para tratamento de dor | |
| Guo et al. | The periodic initial value problem and initial value problem for the modified Boussinesq approximation | |
| DK293890D0 (da) | 3-oe2,(4-arylpiperazin1-yl)-ethoxylaap-cymen, derivater deraf, som er ortho-, meta- og paramonosubstituerede eller -disubstituerede paa phenylringen, fremgangsmaade til fremstilling af saadanne derivater samt laegemidler, hvori forbindelserne er til stede som det aktive middel |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/07/2016, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 22A ANUIDADE. |
|
| B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2728 DE 18/04/2023 POR TER SIDO INDEVIDA. |
|
| B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 27/06/2021 |